Evexia Lifecare Ltd (EVEXIA)

Loading page…

Evexia Lifecare Ltd (EVEXIA) · mywealthgrid

About

Evexia Lifecare Ltd operates as a chemicals trader within the Materials sector with a market cap of ₹264.7 Cr. Recent quarters show significant volatility in revenue (₹6.75 Cr to ₹26.71 Cr over eight quarters) and profitability squeezed to razor-thin margins, with the March 2025 quarter turning to a net loss.

Face value: ₹1

Market cap

₹377 Cr

P/E

237.3×

P/B

0.9×

Dividend yield

ROE

0.4%

ROCE

0.3%

Debt / equity

0.01

OPM

2.6%

EPS (TTM)

₹0.0

Book value

₹2.3

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue in free fall: ₹26.71 Cr (Sep 2024) dropped to ₹15.18 Cr (Mar 2025), a 43% fall in six months that signals severe business deterioration.

Profitability under acute pressure: OPM 3.47%, net profit volatile and negative in recent quarter (₹−0.49 Cr, Mar 2025); EPS essentially zero. Thin margins leave no cushion for cost shocks.

High financial leverage constrains flexibility: D/E 5.3 leaves limited buffer for operational stress or interest-rate rises in a tightening cycle.

Weak institutional confidence and market skepticism: FII 0.12%, DII 0.1%; stock down 37% in 1 year with PE ratio 191.81 suggests investor doubt on recovery.

Generated analysis · source review pending

Growth drivers

Revenue stabilization from current ₹15.18 Cr (Mar 2025), down 43% from ₹26.71 Cr (Sep 2024); verify what caused the collapse and whether conditions can reverse.

Operating margin recovery toward 3–4% range achieved in prior quarters (Mar 2024: 4.36%) from current 0.53%; verify root causes of margin compression.

Debt reduction from unsustainably high D/E 5.3, which limits cash flow availability and refinancing options; verify company's deleveraging roadmap.

Generated analysis · source review pending

1,074 historical price candles were omitted because the exchange source has not been verified.

₹2.0+6.9%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 221×

Cons

−Low return on equity of 0.6% (3-yr avg)
−Thin operating margin of 2.6%
−Modest revenue growth of 0.7% a year over the last 5 years
−Expensive at 237.3× trailing earnings
−Low promoter holding of 3.4%

Research score

Structured signal from quality, growth, valuation and momentum.

49/100

Business quality: 40
Growth: 83

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	107	76	70	56	110	110
COGS	103	71	66	51	89	105
Gross profit	4	5	4	6	22	6
	76	2	3	4	18	3
	-72	2	1	2	4	3
OPM %	-67.7%	3.2%	0.8%	3.5%	3.7%	2.6%
Depreciation	0	0	0	0	2	1
Interest	0	0	1	0	1	0
	74	0	2	1	0	0
Profit before tax	2	2	2	2	1	2
Tax	1	1	1	1	1	1
Tax %	33.3%	60.1%	56.2%	28.5%	35.4%	26.4%
	1	1	1	1	1	2
PAT margin %	1.2%	1.1%	1%	2.5%	0.8%	1.5%
EPS (₹)	0.2	0.1	—	—	0	0
EPS adjusted (₹)	0	0	0	0	0	0
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	61,94,333	62	62	62	62	31	66	71	188	188
Reserves	2,91,310	11	13	16	18	—	24	59	272	247
Minority interest	—	—	—	—	0	—	—	—	7	—
	6,26,250	6	4	7	8	—	705	686	386	3
	36,75,081	128	146	139	56	—	52	67	68	435
Total equity & liabilities	1,07,86,974	208	224	224	143	—	848	883	920	872
	2,27,674	9	9	9	9	9	11	11	50	18
CWIP	19,509	—	—	—	—	—	0	0	0	0
Investments	786	0	0	0	1	—	704	724	717	711
	1,05,39,005	199	216	215	134	—	132	148	154	144
Total assets	1,07,86,974	208	224	224	143	—	848	883	920	872

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	3.5%	6.3%	5.6%	10%	19.6%	5.2%
EBITDA margin %	-67.7%	3.2%	0.8%	3.5%	3.7%	2.6%
EBIT margin %	-68%	2.9%	0.3%	2.7%	2.2%	2%
PAT margin %	1.2%	1.1%	1%	2.5%	0.8%	1.5%
Working capital
Receivable days	156	—	164	282	307	281
Inventory days	12	—	11	8	11	9
Payable days	114	—	186	195	261	197
NWC days	54	—	-11	95	57	93
Leverage
Current ratio	2.09	—	1.86	2.23	1.49	1.5
Debt to EBITDA	—	—	1,215.24	351.88	94.55	1.01
Debt to equity	0.1	—	7.79	5.3	0.84	0.01
Interest coverage	193	22.8	3.8	4.9	2.3	221
Asset turnover	0.74	—	0.08	0.06	0.12	0.13
Return ratios
Return on assets %	0.9%	—	0.1%	0.2%	0.1%	0.2%
Return on capital employed %	2.1%	—	0.3%	0.3%	0.3%	0.3%
Return on equity %	1.6%	—	0.7%	1.1%	0.2%	0.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	9.87%	9.87%	9.87%	9.26%	6.29%	5.87%	3.49%	3.49%	3.49%	3.36%	3.49%	3.36%
	3.36%	3.36%	1.43%	0%	1.03%	1.49%	0.16%	0.16%	0%	0.47%	0.47%	0.12%
	0.28%	0.28%	0.28%	0.26%	0.18%	0.17%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	86.49%	86.49%	88.42%	90.48%	92.5%	92.47%	96.25%	96.25%	96.41%	96.07%	95.94%	96.42%
No. of shareholders	—	—	—	—	—	—	—	—	—	1,48,685	1,46,498	1,44,416

Promoter holding down 6.51 percentage points since Jun 2023.

70 deals · 3 Jan 2022 – 17 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Sept 2026	MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	Bulk	BSE	Buy	98,77,026	₹1.69	₹1.67 Cr
17 Sept 2026	MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	Bulk	BSE	Sell	25,00,000	₹1.78	₹0.45 Cr
16 Sept 2026	SHREE SAIBABA EXIM PRIVATE LIMITED	Bulk	BSE	Buy	2,93,56,550	₹1.78	₹5.23 Cr
16 Sept 2026	MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	Bulk	BSE	Buy	1,12,00,000	₹1.75	₹1.96 Cr
16 Sept 2026	PRIJAL TRADEFIN LLP	Bulk	BSE	Sell	1,03,15,400	₹1.74	₹1.79 Cr
16 Sept 2026	F3 ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	98,45,192	₹1.77	₹1.74 Cr
16 Sept 2026	F3 ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	25,70,192	₹1.79	₹0.46 Cr
16 Sept 2026	PRIJAL TRADEFIN LLP	Bulk	BSE	Buy	18,50,000	₹1.71	₹0.32 Cr
10 Sept 2026	SHREE SAIBABA EXIM PRIVATE LIMITED	Bulk	BSE	Buy	1,38,17,760	₹1.58	₹2.18 Cr
8 Sept 2026	SHREE SAIBABA EXIM PRIVATE LIMITED	Bulk	BSE	Buy	3,82,69,858	₹1.44	₹5.51 Cr

1–10 of 70

1 / 7

Mr. Jayesh Raichandbhai ThakkarExecutive Director-MD
Bhavesh DesaiChief Financial Officer
Mr. Kartik Kumar Bakulchandra MistryNon-Executive - Independent Director
Mr. Hasmukhbhai Dhanjibhai ThakkarNon-Executive - Non Independent Director
Mr. Parth PatelNon-Executive - Independent Director
Mr. Mohammadraza MakraniNon-Executive - Independent Director
Mrs. Krupalibahen Rajeshbhai MehtaNon-Executive - Independent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Evexia Lifecare Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

2

Face value ₹2 → ₹124 May 2022 · ex-date
Face value ₹10 → ₹226 Jul 2021 · ex-date

1

Bonus 1:323 Oct 2015 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

29 announcementsExport CSV

1 Oct 2026, 4:04 pmCompany Update

Evexia Lifecare Ltd - 524444 - Disclosure Under Regulation 7(2)(A) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 And Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011

General PDF

30 Sept 2026, 5:46 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

30 Sept 2026, 11:27 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

29 Sept 2026, 5:30 pmCompany Update

General PDF

28 Sept 2026, 5:32 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

28 Sept 2026, 5:11 pmCompany Update

Disclosure Under Regulation 7(2)(A) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 And Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011

General PDF

22 Sept 2026, 5:39 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

22 Sept 2026, 5:37 pmCompany Update

Disclosure Under Regulation 7(2)(A) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 And Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011

General PDF

Date	Category	Subject	Filing
1 Oct 2026, 4:04 pm	Company Update General	Evexia Lifecare Ltd - 524444 - Disclosure Under Regulation 7(2)(A) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 And Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011	PDF
30 Sept 2026, 5:46 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	3.5%	6.3%	5.6%	10%	19.6%	5.2%
EBITDA margin %	-67.7%	3.2%	0.8%	3.5%	3.7%	2.6%
EBIT margin %	-68%	2.9%	0.3%	2.7%	2.2%	2%
PAT margin %	1.2%	1.1%	1%	2.5%	0.8%	1.5%
Working capital
Receivable days	156	—	164	282	307	281
Inventory days	12	—	11	8	11	9
Payable days	114	—	186	195	261	197
NWC days	54	—	-11	95	57	93
Leverage
Current ratio	2.09	—	1.86	2.23	1.49	1.5
Debt to EBITDA	—	—	1,215.24	351.88	94.55	1.01
Debt to equity	0.1	—	7.79	5.3	0.84	0.01
Interest coverage	193	22.8	3.8	4.9	2.3	221
Asset turnover	0.74	—	0.08	0.06	0.12	0.13
Return ratios
Return on assets %	0.9%	—	0.1%	0.2%	0.1%	0.2%
Return on capital employed %	2.1%	—	0.3%	0.3%	0.3%	0.3%
Return on equity %	1.6%	—	0.7%	1.1%	0.2%	0.4%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Uniphos Enterprises LimitedUNIENTERUNIENTER	₹605 Cr	₹605 Cr	₹26 Cr	₹-4 Cr	-11.7%	₹20 Cr	64.7%	0.8%	0.8%	-12
Veritas (India) LtdVERITASVERITAS	₹397 Cr	₹827 Cr	₹3,113 Cr	₹85 Cr	2.7%	₹20 Cr	0.6%	1.5%	0.7%	110
Vinyl Chemicals (India) LimitedVINYLINDIAVINYLINDIA	₹392 Cr	₹393 Cr	₹601 Cr	₹12 Cr	1.7%	₹19 Cr	2.5%	17.1%	12.8%	32
Evexia Lifecare LtdEVEXIAEVEXIA	₹377 Cr	₹380 Cr	₹110 Cr	₹3 Cr	2.6%	₹2 Cr	1.5%	0.3%	0.4%	93
Bhavik Enterprises LtdBHAVIKBHAVIK	₹334 Cr	—	₹628 Cr	₹17 Cr	2.7%	₹14 Cr	2.2%	—	—	—
Shiv Texchem LtdSHIVTEXCHEMSHIVTEXCHEM	₹269 Cr	—	₹2,776 Cr	₹136 Cr	4.9%	₹78 Cr	2.8%	—	—	—
A-1 LtdA1LA1L	₹263 Cr	₹304 Cr	₹343 Cr	₹12 Cr	3.5%	₹6 Cr	1.8%	18.4%	11.5%	78
Shankar Lal Rampal Dye-Chem LimitedSRDSRD	₹244 Cr	₹269 Cr	₹478 Cr	₹26 Cr	4.2%	₹18 Cr	2.9%	16.6%	11.6%	87
Mysore Petro Chemicals LtdMYSORPETROMYSORPETRO	₹79 Cr	₹79 Cr	₹33 Cr	₹-6 Cr	-17.8%	₹21 Cr	22.3%	1.4%	3.4%	86
Aureate Tradde LtdAUREATEAUREATE	₹64 Cr	—	₹150 Cr	₹9 Cr	6%	₹5 Cr	3.5%	—	—	—
Yash Chemex LtdYASHCHEMYASHCHEM	₹53 Cr	₹69 Cr	₹144 Cr	₹1 Cr	0.9%	₹2 Cr	1.7%	7.6%	5.1%	148
Laffans Petrochemicals LtdLAFFANSQLAFFANSQ	₹23 Cr	₹24 Cr	₹8 Cr	₹-2 Cr	-44.7%	₹2 Cr	8.3%	0.4%	0.6%	-11

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-12	-1	-3	2	-6	-3	17	0	-23
	-6	0	2	-2	8	-697	-17	-29	53
	18	1	1	1	-1	699	1	32	-28
Net cash flow	-0	0	-0	0	1	-1	0	3	2
Free cash flow	-18	-1	—	2	-8	—	—	-7	-27
CFO / Operating profit %	—	—	—	—	-237.2%	-543.1%	872.8%	7.1%	-818.1%

Evexia Lifecare Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

2

1

Announcements

1

2

1

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Evexia Lifecare Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits2

Bonus issues1

Announcements

Board meetings1

Stock splits2

Bonus issues1

Ratio timeline

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

2

1

1

2

1